Handa Therapeutics LLC.: Handa Therapeutics Acquires FDA Approved Chronic Myeloid Leukemia Drug, PHYRAGO Tablets
PHYRAGO Represents the First and Only Improved Version of SPRYCEL® That Can Be Safely Co-administered With Gastric Acid-Reducing Agents TAIPEI, TAIWAN / ACCESSWIRE / January 15, 2025 / Handa Pharmaceu ...
PharmiWeb8h
Handa Therapeutics Acquires FDA Approved Chronic Myeloid Leukemia Drug, PHYRAGO (dasatinib) Tablets
PHYRAGO™ Represents the First and Only Improved Version of SPRYCEL® That Can Be Safely Co-administered With Gastric Acid-Reducing Agents TAIPEI, TAIWAN / ACCESSWIRE / January 15, 2025 / Handa ...
BMJ13h
Association of proton pump inhibitors and concomitant drugs with risk of acute kidney injury: a nested case–control study
Objectives This study aimed to assess whether the combined use of proton pump inhibitors (PPIs) with non-steroidal anti-inflammatory drugs (NSAIDs) or antibiotics (penicillins, macrolides, ...